United Therapeutics Corporation (UTHR) Investor Relations Documents

United Therapeutics Corporation (UTHR) investor relations documents from the company's IR site: 5 presentations, 35 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

Download Presentation PDF: United Therapeutics reports $783M revenue in 2Q 2026, driven by strong Unituxin sales, and highlights positive TETON-2 trial results for Nebulized Tyvaso.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-17Press releaseUnited Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatme
2026-08-05PresentationDownload Presentation PDF
2026-07-23Press releaseUnited Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
2026-07-22Press releaseUnited Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August
2026-07-02Press releaseUnited Therapeutics Corporation Acquires Thymmune Therapeutics
2026-07-02Press releaseDownload pdf
2026-06-29Press releaseDownload pdf
2026-05-27Press releaseUnited Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
2026-05-26Press releaseDOWNLOAD PDF
2026-05-18Press releaseDOWNLOAD PDF
2026-05-17Press releaseUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and P
2026-05-17Press releaseDOWNLOAD PDF
2026-05-15Press releaseDOWNLOAD PDF
2026-05-12Press releaseUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
2026-05-11Press releaseDOWNLOAD PDF
2026-05-11Press releaseDOWNLOAD PDF
2026-05-06Press releaseUnited Therapeutics Corporation Reports First Quarter 2026 Financial Results
2026-05-06PresentationDOWNLOAD OUR CORPORATE PRESENTATION
2026-05-05Press releaseDownload pdf
2026-04-22Press releaseUnited Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2
2026-04-22Press releaseDownload pdf
2026-04-22Press releaseUnited Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and X
2026-04-20Press releaseDownload pdf
2026-04-08Press releaseDownload pdf
2026-03-30Press releaseDownload pdf
2026-03-11Press releaseDownload pdf
2026-03-03Press releaseUnited Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
2026-03-03Press releaseDownload pdf
2026-03-02Press releaseUnited Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulm
2026-03-02Press releaseDownload pdf
2026-03-02PresentationDownload Presentation PDF
2026-02-25Press releaseUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-25PresentationDownload Presentation PDF
2026-02-24Press releaseDownload pdf
2026-02-24Fact sheetDownload Fact Sheet PDF
2026-02-23Press releaseUnited Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-23Press releaseDownload pdf
2026-02-11Press releaseUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on
2026-02-11Press releaseDownload pdf
2026-01-26Press releaseDownload pdf

UTHR overview · UTHR earnings · UTHR financials · UTHR KPIs · UTHR documents · UTHR ownership · UTHR peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.